Benjamin J Gigliotti
Overview
Explore the profile of Benjamin J Gigliotti including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
10
Citations
238
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Tessnow A, Gigliotti B, Perkins J, Schneiderman C, Pinsky B, Guo D, et al.
Endocr Pract
. 2024 Dec;
31(3):359-365.
PMID: 39667670
Objective: Recent data using NHANES and Optum Claims data (OCD) showed an increase in primary hypothyroidism (HT) prevalence in the United States following the 2002 NHANES III report. Using these...
2.
Carafone L, Knutson A, Gigliotti B
Semin Reprod Med
. 2024 Dec;
42(3):178-192.
PMID: 39667368
Hashimoto thyroiditis and Graves' disease are autoimmune thyroid disorders that are common in women of reproductive age and have a complex relationship with female fertility and health of the maternal-fetal...
3.
Gigliotti B, Brooks J, Wirth L
Mol Cell Endocrinol
. 2024 Jun;
592:112295.
PMID: 38871174
Medullary thyroid carcinoma (MTC) is a rare primary neuroendocrine thyroid carcinoma that is distinct from other thyroid or neuroendocrine cancers. Most cases of MTC are sporadic, although MTC exhibits a...
4.
Gigliotti B, Jasim S
Endocrine
. 2023 Oct;
83(2):251-258.
PMID: 37824045
Purpose: This review focuses on post-operative thyroid hormone replacement and thyrotropin suppression therapy in patients with differentiated thyroid cancer. Methods: A clinical review. Results: Differentiated thyroid cancers (DTC), including papillary...
5.
Gopal R, Vantaku V, Panda A, Reimer B, Rath S, To T, et al.
Cancer Discov
. 2023 Jun;
13(8):1904-1921.
PMID: 37262067
Significance: HCC harbors abundant mitochondria, mitochondrial DNA mutations, and chromosomal losses. Using a CRISPR-Cas9 screen inspired by transcriptomic and metabolomic profiling, we identify molecular effectors essential for cell fitness. We...
6.
Gopal R, Kubler K, Calvo S, Polak P, Livitz D, Rosebrock D, et al.
Cancer Cell
. 2018 Aug;
34(2):242-255.e5.
PMID: 30107175
Hürthle cell carcinoma of the thyroid (HCC) is a form of thyroid cancer recalcitrant to radioiodine therapy that exhibits an accumulation of mitochondria. We performed whole-exome sequencing on a cohort...
7.
Lubitz C, Zhan T, Gunda V, Amin S, Gigliotti B, Fingeret A, et al.
Thyroid
. 2018 Jan;
28(3):328-339.
PMID: 29378474
Background: BRAF is the most common mutation in papillary thyroid carcinoma (PTC) and can be associated with aggressive disease. Previously, a highly sensitive blood RNA-based BRAF assay was reported. The...
8.
Rosenbaum M, Gigliotti B, Pai S, Parangi S, Wachtel H, Mino-Kenudson M, et al.
Endocr Pathol
. 2018 Jan;
29(1):59-67.
PMID: 29372535
Poorly differentiated thyroid carcinoma (PDTC) is an aggressive form of thyroid cancer that currently has limited effective treatment options. Immune checkpoint inhibitors (ICIs) have shown to be an effective treatment...
9.
Frisch B, Porter R, Gigliotti B, Olm-Shipman A, Weber J, OKeefe R, et al.
Blood
. 2009 Sep;
114(19):4054-63.
PMID: 19726721
Microenvironmental signals can determine hematopoietic stem cell (HSC) fate choices both directly and through stimulation of niche cells. In the bone marrow, prostaglandin E(2) (PGE(2)) is known to affect both...
10.
Weber J, Forsythe S, Christianson C, Frisch B, Gigliotti B, Jordan C, et al.
Bone
. 2006 May;
39(3):485-93.
PMID: 16647886
We previously demonstrated that activation of the Parathyroid Hormone Receptor (PTH1R) in osteoblastic cells increases the Notch ligand Jagged1 and expands hematopoietic stem cells (HSC) through Notch signaling. However, regulation...